RxDoctor Payments Data

Marcus Quek, MD

Urology · Maywood, ILNPI 1457325433

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 47.5% of the total. 2025 is the largest year on record at $4,680, 8.7 times the $537 reported in 2019.

$9,101in general payments, 2019–2025

Across 29 payments — averaging $313.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$4K
  • Urogen Pharma, Inc.$3K
  • Myriad Genetic Laboratories, Inc.$263
  • Boston Scientific$262
  • Dendreon Pharmaceuticals LLC$226
  • Johnson & Johnson$211
  • plus $852 from 7 others
$61,392in research payments, 2019–2025

Across 5 payments — averaging $12,278 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astrazeneca UK Limited$61K
  • Urogen Pharma, Inc.$352

What the payments were for

  • Consulting fees$2,80031%
  • Speaking & faculty fees$4,27547%
  • Travel & lodging$1402%
  • Food & beverage$1,88721%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,101 in reported general payments places this provider in the 80th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois

Medicare billing

Part B allowed, 2024
$219,790
Medicare patients
670
Services billed
1,471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron28$20,703
Methenamine Hippurate34$3,654
Tamsulosin Hcl199$2,800
Finasteride147$1,800
Potassium Citrate ErPotassium Citrate25$1,703
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$1,118
Oxybutynin Chloride32$583
Bicalutamide20$462
Oxybutynin Chloride ErOxybutynin Chloride23$435
Cephalexin25$301
Ampicillin Trihydrate16$239
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$235
Sildenafil Citrate25$152
Ciprofloxacin Hcl33$112
Hydrochlorothiazide16$80

Paid to pharmacies, not to this prescriber.

Other urology in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →